Image de couverture de livre

COMIC: A Bayesian Dose Optimization Design for Drug Combination in Multiple Indications With Application to CAR‐T Therapies

Fuente: Wiley Open Access

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Kai Chen, Kentaro Takeda, Ying Yuan
Format:	Artículo Open Access
Publié:	Wiley 2025
Sujets:	Statistics in Medicine
Accès en ligne:	Acceder al recurso
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

A Biomarker‐Based Dose–Schedule Optimization Design for Immunotherapy Trials
par: Yingjie Qiu, et autres
Publié: (2026)

A Generalized Phase I/II Dose Optimization Trial Design With Multi‐Categorical and Multi‐Graded Outcomes
par: Yichen Yan, et autres
Publié: (2025)

BAR12 : Bayesian Autoregressive Phase 1‐2 Design for Cell Therapy Trials With Manufacturing Changes
par: Cheng‐Han Yang, et autres
Publié: (2026)

Towards Efficient Time‐to‐Event Dose‐Escalation Guidance of Multi‐Cycle Cancer Therapies
par: Lukas A. Widmer, et autres
Publié: (2025)

DOD ‐ SSR : An Adaptive Seamless Phase II / III Design With Dose Optimization Decision and Sample Size Re‐estimation
par: Meizi Liu, et autres
Publié: (2025)

On Inclusion of Covariates in Model Based Dose Finding Clinical Trial Designs
par: Adrien Ollier, et autres
Publié: (2025)

A Partially Randomized Patient Preference, Sequential, Multiple‐Assignment, Randomized Trial Design Analyzed via Weighted and Replicated Frequentist and Bayesian Methods
par: Marianthie Wank, et autres
Publié: (2024)

The Win Ratio Approach in Bayesian Monitoring for Two‐Arm Phase II Clinical Trial Designs With Multiple Time‐To‐Event Endpoints
par: Xinran Huang, et autres
Publié: (2024)

Sample Size Calculation in Dose Optimization Trials Using the Margin of Practical Non‐Inferiority
par: Hakim‐Moulay Dehbi, et autres
Publié: (2025)

Flexible Bayesian Inference for Identifying Significantly Correlated Multiple Pathway Sets
par: PhilGeun Jin, et autres
Publié: (2026)

Bayesian Adaptive Enrichment Design for Continuous Biomarkers
par: Yue Tu, et autres
Publié: (2025)

Bayesian Prediction of Event Times Using Mixture Model for Blinded Randomized Controlled Trials
par: Jingyan Fu, et autres
Publié: (2025)

Probability of Success for Establishing Noninferiority Across Multiple Visits: Extension of Covariate‐Adjusted Bayesian Hierarchical Modeling Framework
par: Yujie Zhao, et autres
Publié: (2026)

A Bayesian Two‐Step Multiple Imputation Approach Based on Mixed Models for Missing EMA Data
par: Yiheng Wei, et autres
Publié: (2025)

A Precision Mixture Risk Model to Identify Adverse Drug Events in Subpopulations Using a Case‐Crossover Design
par: Yi Shi, et autres
Publié: (2024)

A Tutorial on Bayesian Multi‐Study Factor Analysis With Applications in Nutrition and Genomics
par: Mavis Liang, et autres
Publié: (2026)

A Bayesian Causal Model for Matrix‐Valued Exposures With Applications to Radiotherapy Planning
par: Zijin Liu, et autres
Publié: (2026)

Bayesian Longitudinal Network Regression With Application to Brain Connectome Genetics
par: Chenxi Li, et autres
Publié: (2025)

A Bayesian Mixture of Exponential Family Factor Models for Uncovering Disease Progression Subtypes
par: Kai Kang, et autres
Publié: (2025)

Bayesian Ordered Lattice Design for Phase I Clinical Trials
par: Gi‐Ming Wang, et autres
Publié: (2026)

Bayesian Borrowing With Multiple Heterogeneous Historical Studies Using Order Restricted Normalized Power Prior
par: Zifei Han, et autres
Publié: (2025)

Design and sample size determination for multiple‐dose randomized phase II trials for dose optimization
par: Peng Yang, et autres
Publié: (2024)

A Seamless Design for the Combination of a Case–Control and a Cohort Diagnostic Accuracy Study
par: Eric Bibiza‐Freiwald, et autres
Publié: (2025)

A Bayesian Treatment Selection Design for Phase II Randomised Cancer Clinical Trials
par: Moka Komaki, et autres
Publié: (2026)

BOIN ‐ MEM : A Two‐Stage Design for Dose Optimization With Information Borrowing Across Dose Levels and Stages in Oncology Phase I/ II Trials
par: Ryo Kitabayashi, et autres
Publié: (2025)

Testing for Similarity of Dose Response in Multiregional Clinical Trials
par: Holger Dette, et autres
Publié: (2025)

A Biomarker Signature‐Guided Clinical Trial Design for Precision Medicine
par: Yuan Li, et autres
Publié: (2025)

BEAM: Bayesian Hybrid Design With Adaptive Sample Size Through Multisource Exchangeability Modeling
par: Feng Tian, et autres
Publié: (2025)

Dose Individualization for Phase I Cancer Trials With Broadened Eligibility
par: Rebecca B. Silva, et autres
Publié: (2024)

Minimum Area Confidence Set Optimality for Simultaneous Confidence Bands for Percentiles With Applications to Drug Shelf‐Life Estimation
par: Lingjiao Wang, et autres
Publié: (2025)

Bayesian Variable Selection for High‐Dimensional Mediation Analysis: Application to Metabolomics Data in Epidemiological Studies
par: Youngho Bae, et autres
Publié: (2026)

Estimating Risk Factors for Pathogenic Dose Accrual From Longitudinal Data
par: Daniel K. Sewell, et autres
Publié: (2025)

Time‐Dependent ROC Curve for Multiple Longitudinal Biomarkers and Its Application in Diagnosing Cardiovascular Events
par: Lizhe Sun, et autres
Publié: (2025)

Bayesian Network Meta‐Analysis With One or Two Continuous Outcomes Measured at Multiple Time Points Using Gaussian Random Walks With Drift
par: Pai‐Shan Cheng, et autres
Publié: (2026)

Analysis of Covariance in General Factorial Designs Through Multiple Contrast Tests Under Variance Heteroscedasticity
par: Matthias Becher, et autres
Publié: (2025)

ROMI: A Randomized Two-Stage Basket Trial Design to Optimize Doses for Multiple Indications
par: Wang, Shuqi, et autres
Publié: (2024)

A New Algorithm for Sampling Parameters in a Structured Correlation Matrix With Application to Estimating Optimal Combinations of Muscles to Quantify Progression in Duchenne Muscular Dystrophy
par: Michael K. Kim, et autres
Publié: (2025)

Accounting for Carryover Toxicity in Phase I Clinical Trials with Intra‐Patient Dose Escalation
par: Chloe E. Falke, et autres
Publié: (2025)

Combining Biomarkers to Improve Diagnostic Accuracy in Detecting Diseases With Group‐Tested Data
par: Jin Yang, et autres
Publié: (2024)

Survival Analysis Under the Aalen's Additive Hazards Model With Covariate Measurement Error: Application to Causal Mediation Analysis
par: Xialing Wen, et autres
Publié: (2025)